Serve You Rx Launches Biosimilar Advantage Formulary to Provide Lower Upfront Cost Options for Specialty Drugs

Serve You Rx, a full-service pharmacy benefit manager (PBM) based in Milwaukee, has launched its new Biosimilar Advantage Formulary. This strategy aims to accelerate the adoption of biosimilars by positioning them with lower upfront costs as preferred treatments, while reference brands are excluded or non-preferred.

Despite potential cost savings, the adoption of biosimilars in the United States has been sluggish. According to a report by the IQVIA Biosimilars Council, biosimilars capture only about 2% of new-to-brand prescriptions. The Biosimilar Advantage Formulary seeks to promote the use of biosimilars and improve accessibility for plan members.

"By promoting these products through preferred formulary positioning, we can help our clients realize upfront savings," said Justin Jasniewski, CEO of Serve You Rx.

The formulary evaluates FDA-approved indications, pricing, available rebates, and other key attributes to enhance affordability for plan members. According to Ted Boylan, President of Serve You Rx, this effort reflects the company's commitment to navigating the evolving pharmaceutical landscape and delivering cost-effective solutions.